These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 21439671

  • 1. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
    Heigener DF, Wu YL, van Zandwijk N, Mali P, Horwood K, Reck M.
    Lung Cancer; 2011 Nov; 74(2):274-9. PubMed ID: 21439671
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
    Boyer M, Horwood K, Pavlakis N, De Souza P, Millward M, Stein B, Johnston M, Abell F, Rischin D.
    Asia Pac J Clin Oncol; 2012 Sep; 8(3):248-54. PubMed ID: 22898114
    [Abstract] [Full Text] [Related]

  • 3. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D.
    J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
    [Abstract] [Full Text] [Related]

  • 4. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
    Tiseo M, Gridelli C, Cascinu S, Crinò L, Piantedosi FV, Grossi F, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P, Ardizzoni A.
    Lung Cancer; 2009 May; 64(2):199-206. PubMed ID: 18951651
    [Abstract] [Full Text] [Related]

  • 5. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, Hachiya T, Ohura N.
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [Abstract] [Full Text] [Related]

  • 6. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR, Burris HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD.
    J Clin Oncol; 2011 Jun 20; 29(18):2582-9. PubMed ID: 21576636
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
    Merimsky O, Cheng CK, Au JS, von Pawel J, Reck M.
    Oncol Rep; 2012 Aug 20; 28(2):721-7. PubMed ID: 22614912
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.
    Lung Cancer; 2012 Jan 20; 75(1):82-8. PubMed ID: 21684626
    [Abstract] [Full Text] [Related]

  • 9. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.
    Casal Rubio J, Fírvida-Pérez JL, Lázaro-Quintela M, Barón-Duarte FJ, Alonso-Jáudenes G, Santomé L, Afonso-Afonso FJ, Amenedo M, Huidobro G, Campos-Balea B, López-Vázquez MD, Vázquez S.
    Cancer Chemother Pharmacol; 2014 Mar 20; 73(3):451-7. PubMed ID: 24352251
    [Abstract] [Full Text] [Related]

  • 10. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J.
    Clin Ther; 2005 Oct 20; 27(10):1513-34. PubMed ID: 16330289
    [Abstract] [Full Text] [Related]

  • 11. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
    Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K, SIGN Study Group.
    Anticancer Drugs; 2006 Apr 20; 17(4):401-9. PubMed ID: 16549997
    [Abstract] [Full Text] [Related]

  • 12. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA, TRIBUTE Investigator Group.
    J Clin Oncol; 2005 Sep 01; 23(25):5892-9. PubMed ID: 16043829
    [Abstract] [Full Text] [Related]

  • 13. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
    Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P.
    J Clin Oncol; 2004 Aug 15; 22(16):3238-47. PubMed ID: 15310767
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
    Clément-Duchêne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA.
    Lung Cancer; 2012 Oct 15; 78(1):57-62. PubMed ID: 22809813
    [Abstract] [Full Text] [Related]

  • 15. Erlotinib in the treatment of advanced squamous cell NSCLC.
    Fiala O, Pesek M, Finek J, Krejci J, Havel L, Hrnciarik M, Salajka F, Bortlicek Z, Benesova L, Minarik M.
    Neoplasma; 2013 Oct 15; 60(6):676-82. PubMed ID: 23906302
    [Abstract] [Full Text] [Related]

  • 16. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
    Spigel DR, Lin M, O'Neill V, Hainsworth JD.
    Cancer; 2008 Jun 15; 112(12):2749-55. PubMed ID: 18438878
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
    Matsuura S, Inui N, Ozawa Y, Nakamura Y, Toyoshima M, Yasuda K, Yamada T, Shirai T, Suganuma H, Yokomura K, Suda T, Chida K.
    Jpn J Clin Oncol; 2011 Aug 15; 41(8):959-63. PubMed ID: 21715361
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A.
    J Clin Oncol; 2007 Oct 20; 25(30):4743-50. PubMed ID: 17909199
    [Abstract] [Full Text] [Related]

  • 19. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M.
    Lung Cancer; 2006 Jan 20; 51(1):89-96. PubMed ID: 16290256
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
    Zhou S, Ren S, Yan L, Zhang L, Tang L, Zhang J, Zhou C.
    Respirology; 2009 Jul 20; 14(5):709-15. PubMed ID: 19659649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.